Events & Presentations

Featured Event

Featured Presentation

Upcoming Events

Date Event
April 12, 2018 02:10 AM EDT
Boston, MA United States

Speaker(s):

  • Dr. Tony Ting, Vice President of Regenerative Medicine and Head of Cardiopulmonary Programs
May 10, 2018 04:30 PM EDT

Athersys, Inc. (Nasdaq:ATHX) will release its first quarter 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, May 10, 2018, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call.

Date: May 10, 2018
Time: 4:30 p.m. (Eastern Time)
Telephone access: US and Canada - (800) 273-1254
Telephone access: International - (973) 638-3440
Access code: 1189915

June 18, 2018 11:00 AM EDT

We invite all of our shareholders to attend our annual meeting, scheduled for Monday June 18th at the Westin Cleveland Hotel, located at 777 St. Clair Ave NE in Cleveland. A continental breakfast will be served at 11 AM and the meeting will follow at 11:30 AM.

June 19, 2018 01:50 PM AEST
Melbourne, Australia
Walter and Eliza Hall Institute of Medical Research

Speaker(s):

  • Sarah Busch, PhD, Associate Director of Regenerative Medicine - Athersys, Inc.

Dr. Sarah Busch will present at the Pre-Meeting Education Session II: Cellular Therapy in the Nervous System.

Pre-Meeting Education Schedule

August 7, 2018 04:30 PM EDT

Athersys, Inc. (NASDAQ:ATHX) will release its second quarter 2018 financial results at approximately 4:00 PM Eastern Time on Tuesday, August 7th, 2018, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Laura Campbell, Senior Vice President of Finance and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:

Date August 7, 2018
Time 4:30 p.m. (Eastern Time)
Telephone access: US and Canada (800) 273-1254
Telephone access: International (973) 638-3440
Access code 5144048
October 3, 2018 05:30 PM PDT
La Jolla, CA
Ballroom 1 at the Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037

Speaker(s):

  • Gil Van Bokkelen Ph.D., Chairman and CEO

Dr. Van Bokkelen will provide a brief overview of the Athersys’ clinical pipeline, focusing on the ongoing Phase 3 trial of MultiStem® cell therapy for the treatment of ischemic stroke that has received Fast Track and RMAT designation from the U.S. Food and Drug Administration, positive scientific advice from the European Medicines Agency, and is being conducted under a Special Protocol Assessment (SPA).

In addition, Dr. Van Bokkelen has been invited to speak at two conference workshops, where he will describe the Company’s progress working in collaboration with Healios K.K. under the innovative regenerative medicine regulatory framework implemented in Japan as part of the “Doing Business in Japan” workshop. During the “Readiness Strategies for Cell Therapy – Commercial Manufacturing” workshop, Dr. Van Bokkelen will discuss commercial manufacturing approaches and technologies for cellular therapies.

Event: Doing Business in Japan Workshop: Development of an “Off the Shelf” Cell Therapy for Ischemic Stroke and Other Indications Under the Regenerative Medicine Regulatory Framework in Japan
Date: October 3, 2018
Time: 7:50 – 8:05 am Pacific Time
Location: Magnolia Room at the Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037

Event: Athersys Corporate Overview
Date: October 3, 2018
Time: 5:30 – 5:45 pm Pacific Time
Location: Ballroom 1 at the Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037

Event: Readiness Strategies for Cell Therapy – Commercial Manufacturing Workshop, Section 3 Technology
Date: October 4, 2018
Time: 8:10 – 8:35 am Pacific Time
Location: Learning Theater at the Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 9203

November 6, 2018 04:30 PM EST

Telephone access: US and Canada (800) 273-1254
Telephone access: International (973) 638-3440
Access code 7396506

January 7, 2019
San Francisco, CA

Athersys will be attending the JP Morgan Healthcare conference, where companies gather to share exciting advances that are driving medical #innovation to help transform clinical care for patients.

April 9, 2019 10:00 AM ET
Westin Grand Central Hotel, New York City

Speaker(s):

  • Gil Van Bokkelen, Chairman and CEO
May 9, 2019
Boston, MA

Speaker(s):

  • Greg Liposky, MBA, Senior Vice President of Commercial Manufacturing at Athersys

Greg Liposky, MBA, Senior Vice President of Commercial Manufacturing at Athersys will be chairing the day 2 session and giving a presentation at 10 AM ET titled “Establishing Long-Term Strategic Plans for Commercial Manufacturing of Allogeneic Cell Therapies”. The presentation will include an overview of Athersys, MultiStem- a novel therapy for the treatment of ischemic stroke, and discuss the factors to consider in planning for product commercialization, such as process scalability, process reliability and process reproducibility.

May 14, 2019 08:00 AM

Thank you to everyone that attended the event. To view a highlight video of the event, please fill out this form. Your name and a valid email address is required for viewing.

May 20, 2019
Dallas, Texas

Speaker(s):

  • Dr. Geoff Bellingan, Medical Director at University College London Hospitals

Dr. Bellingan will present the data from the Athersys ARDS trial. His presentation is titled “Primary Analysis of a Phase 1/2 Study to Assess MultiStem® Cell Therapy, a Regenerative Advanced Therapy Medicinal Product (ATMP), in Acute Respiratory Distress Syndrome (MUST-ARDS)” Monday May 20, 2019 9:15 AM - 11:15 AM

June 12, 2019 08:30 AM EDT
The Ritz-Carlton – The Hideaway Room, 1515 W. 3rd Street, Cleveland, Ohio 44113

Registration opens at 7:30 AM EDT

Advanced registration is required, please register here: https://www.athersys.com/investors/resources/annual-information/default.aspx

August 7, 2019 04:30 PM EDT

Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, August 7, 2019, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows:

Date - August 7, 2019
Time - 4:30 p.m. (Eastern Time)
Telephone access: US and Canada (877) 396-3286
Telephone access: International (647) 689-5528
Encore Passcode (needed for the replay only) 5087881

We encourage shareholders to listen using the webcast link and to use the phone line if you intend to ask a question. A replay will be available on the webcast at www.athersys.com under the investors section approximately two hours after the call has ended. Shareholders may also call in for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on August 14, 2019 by dialing (800) 585-8367 or (416) 621-4642 and entering Encore passcode 5087881.

September 13, 2019 08:45 AM CT
Monona Terrace Community & Convention Center, 1 John Nolen Drive, Madison, Wisconsin 53703

Speaker(s):

  • Dr. Gil Van Bokkelen, Chairman and CEO

Plenary 1: Mesenchymal and Progenitor Stem Cells: Results from the Clinic and the Future of Living Drugs

Mesenchymal and Progenitor Stem Cells have begun to show clear evidence of efficacy outstanding safety profile in early clinical trials. This session aims to bring together some of those trials that are in the most advanced stages of testing. The presenters will each highlight the results from their efforts to with an emphasis on the lessons learned from these trials and their approach toward answering critical questions for the future of these technologies including purity, potency and logistics considerations.

For more information about the conference, please visit ISCT North America 2019. 

 

October 3, 2019 05:45 PM PT
Park Hyatt Aviara Resort, 7100 Aviara Resort Dr., Carlsbad, CA 92011

Speaker(s):

  • Dr. Gil Van Bokkelen, Chairman & CEO

BlueRock Therapeutics Ballroom

For more information, please click here.

October 29, 2019 02:25 PM ET
Jupiter, Florida

Speaker(s):

  • Gil Van Bokkelen, Chairman and Chief Executive Officer

Track 2, Preserve Ballroom B

For more information, click here


 

November 13, 2019 12:15 PM IST
Glenlo Abbey Hotel, National University of Galway, University Road, Galway,Ireland H91TK33

Speaker(s):

  • Bart Vaes, Associate Director, Site Leader, ReGenesys

Clinical Development of MultiStem(R) Therapies

For more information: please click here.

December 11, 2019 08:00 AM PT
San Diego, CA

Speaker(s):

  • Dr. Robert (Willie) Mays, Ph.D., Vice President of Regenerative Medicine and Head of Neuroscience Programs

Wednesday, December 11, 2019

Cellular Therapies and Novel Blood Products in Trauma and Critical Care – The Future of Transfusion Medicine

Session 2: Challenges in Product Development, Cell Production and Processing

Cell Production Panel

4:25 – 5:25 p.m.

 

Friday, December 13, 2019

Cellular Therapies in Trauma and Critical Care Medicine

Session 1: Cellular Therapies in Critical Care Medicine

 “Multipotent Adult Progenitor Cells in ARDS”

9:50 – 10:10 a.m.

January 21, 2020 10:45 AM ET
Miami, FL

Speaker(s):

  • Anthony Ting and Robert W. Mays, VP's of Regenerative Medicine

January 21, 2020

10:45 a.m.
Treatment of Acute Clinical Indications with Cell Therapy
by Anthony Ting, PhD, VP of Regenerative Medicine, Athersys, Inc.


January 22, 2020

9:15 a.m.
Panel Discussion: Recent Advances on RMAT and TRIP
by Robert W. Mays, VP of Regenerative Medicine and Head of Neuroscience Programs, Athersys, Inc.


January 24, 2020

9:05 a.m.
Clinical Development of MultiStem, an Adult Stem Cell Therapy for Treatment of Acute Injuries of the Central Nervous System
by Robert W. Mays, VP of Regenerative Medicine and Head of Neuroscience Programs, Athersys, Inc.



May 21, 2020 11:00 AM ET

Speaker(s):

  • Eric Jenkins, M.D., Senior Medical Director and Head of Clinical Operations

Cell Therapy Treatments for COVID-19

Thursday, May 21, 2020 at 11 AM EST

This webinar will highlight potential treatments for Acute Respiratory Distress syndrome (ARDS) in COVID-19 patients. Two therapeutic developers, Athersys and Pluristem Therapeutics, will present on their treatment approaches and plans for near term clinical trials.

Speakers:


Eric Jenkins, M.D., Senior Medical Director and Head of Clinical Operations, Athersys

Dr. Jenkins rejoined Athersys as Medical Director in 2016, where he is responsible for medical oversight of all clinical development activities. With 20 years of clinical experience, he contributes medical expertise to the Company’s long-term strategic planning and serves as the medically-informed voice for external communications with clinical investigators, regulators, key opinion-leaders and patient communities. In addition, Dr. Jenkins currently leads the pure-commercial medical affairs activities, including preparation for market access, coding and reimbursement for MultiSteam cell therapy products following approval.

Racheli Ofir, Ph.D., Vice President Research and Intellectual Property, Pluristem Therapeutics

Dr. Ofir joined Pluristem in 2007, as Vice President of research and intellectual property. The Research Department examines the various cells developed by the company, the properties of those cells and their mechanisms of action by using molecular methods and animal models to test the safety and efficacy. The IP department is responsible for intellectual property strategy development as well as the research that supports the IP. Dr. Ofir is responsible for leading projects involving the characterization of PLX cells, Pluristem’s leading placenta derived cell product candidate, including evaluating the biological activity of the cells in in-vitro and animal studies. She is responsible for the studies which determines the safety profile and pharmacokinetics of PLX cells.

RSVP to listen the free webinar here.

May 28, 2020 02:00 PM ET

Speaker(s):

  • Anthony Ting, Vice President, Regenerative Medicine, Head of CardioPulmonary Programs
  • State of the Art: Success and Failure of Cell Therapy Clinical Trials for Acute and Chronic Lung Diseases - Dr. Ting will present "MultiStem for Acute Respiratory Distress Syndrome (MUST-ARDS study)"
  • Dr. Ting will be the session chair for: Strategies for Commercialization PLENARY Session - Is Big Pharma Ready for Industrial Scale Cell and Gene Therapy?
  • ISCT CSO Global Showcase on Covid-19, Part II 'A New Hope' - Dr. Ting will present "Industry-led Cell Therapy Clinical Trials for COVID-19"

http://www.isct2020.com/

 

June 18, 2020 08:30 AM ET

Welcome to the 2020 Annual Meeting of Stockholders (the “Annual Meeting”) of Athersys, Inc. (“Athersys”). This year our Annual Meeting is taking place in a virtual-only format. 

Only stockholders as of the close of business on Friday, April 24, 2020 (the “Record Date”) or holders of proxies may participate, vote or ask questions at the Annual Meeting. To gain access to the Annual Meeting, you will need the 16-digit control number located on your proxy card. Please keep your control number in a safe place so it is available to you for the meeting. Using this control number, you will be able to participate in the live meeting. Please allow ample time for online check-in, which will begin at 8:15 a.m., Eastern Daylight Time, on June 18, 2020. If you do not have a control number, please contact your broker ahead of time to obtain it.

Agenda

  1. Call Meeting to Order by Gil Van Bokkelen, Chief Executive Officer and Chairman of the Board of Directors of Athersys, Inc.
  1. Introduction of Directors, Director Nominee and Officers.
  1. Introduction of Independent Registered Public Accounting Firm.
  1. Report by Secretary of Mailing.
  1. Presentation of List of Stockholders as of Record Date.
  1. Report of Quorum by the Inspector of the Election.
  1. Nomination and Election of Directors.
  1. Ratify Appointment of Independent Auditor.
  1. Approve, on an Advisory Basis, Named Executive Officer Compensation.
  1. Report of the Inspector of the Election.
  1. Other and Further Business and Adjournment.
  1. General Question and Answer Period.

Rules of Conduct

In fairness to all stockholders and in the interest of an orderly and constructive meeting, the following procedures will apply:

  1. This virtual Annual Meeting of the stockholders of Athersys will follow the order on the agenda.  You need to have held stock as of the close of business on the record date of April 24, 2020 to participate, vote or submit questions while participating in the Annual Meeting. 

  2. To access the Annual Meeting, you will need to enter the 16-digit control number you received with your proxy materials and may enter the meeting starting at 8:15 AM ET on June 18, 2020.  If you have voted your shares prior to the start of the Annual Meeting by proxy or via the internet or telephone, your vote has been received by Athersys’ Inspector of Elections and there is no need to vote those shares during the Annual Meeting, unless you wish to revoke or change your vote.  

  1. During the business portion of the Annual Meeting, all comments should be limited to the relevant agenda items. To submit your comment, type your comment along with your full name, and if applicable, the specific proposal to which your comment relates in the “Ask a Question” field, and click “Submit.” In order to facilitate responses and discussion, all comments should be succinct and limited to one topic. Others will not see your name or your comment, and we will not reveal your identity.

  1. After the business portion of the Annual Meeting has been adjourned, a general update and “Question and Answer” period will follow. Such questions may be submitted in the field provided in the web portal during the Annual Meeting. Please provide your full name along with your question.

  1. To allow as many stockholders as possible the opportunity to be heard, each stockholder will be permitted no more than two questions.

  1. Questions from multiple shareholders on the same topic or that are otherwise related may be grouped, summarized and answered together.

  1. Athersys does not intend to answer questions that are, among other things:

  • Irrelevant to the business of Athersys or to the business of the meeting;

  • Related to material non-public information of Athersys;

  • Related to personal grievances;

  • Derogatory references to individuals or that are otherwise in bad taste;

  • Related to threatened or ongoing legal action or litigation;

  • Repetitious statements already made by another shareholder;

  • In furtherance of the shareholder’s personal or business interests; or

  • Out of order or not otherwise suitable for the conduct of the meeting as determined by the Chairman or Corporate Secretary in their reasonable judgment.

  1. Individual concerns. If there are any matters of individual concern to a shareholder and not of general concern to all shareholders, or if a question posed was not otherwise answered due to time restraints, such matters or questions may be raised separately after the meeting by contacting Investor Relations at ir@athersys.com.

  1. In the event of disorder, technical malfunction or other significant problem that disrupts the meeting, the Chairman may adjourn, recess or expedite the meeting or take such other action that the Chairman determines is appropriate in light of the circumstances. In such case, please stay connected to the meeting website for at least 15 minutes. If the meeting cannot be resumed, (i) all items of the official business of the meeting described in the proxy statement will be deemed to be properly before the meeting; (ii) all proxy and other votes received before the start of the interruption will be deemed to have been validly cast; and (iii) the official business of the meeting will be deemed to have been validly completed and the meeting adjourned immediately thereafter.

  1. No one attending via the webcast is permitted to use any audio or recording device. 

  1. Copying of materials presented at the meeting is prohibited, including screenshots.

  1. Forward Looking Statements. We may make forward-looking statements during the Annual Meeting, which are subject to various risks and uncertainties. Please see the Athersys filings with the Securities and Exchange Commission (SEC) for more information on the risks that could cause our actual results to differ from these forward-looking statements.

The violation of any of these rules will be considered cause for expulsion from the meeting.

Thank you for your cooperation and participation.



Events Archive